Loading clinical trials...
Loading clinical trials...
An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-267 With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Infection
Conditions
Interventions
ABT-450
ABT-267
+2 more
Start Date
September 1, 2011
Primary Completion Date
May 1, 2013
Completion Date
May 1, 2013
Last Updated
July 11, 2016
NCT05361603
NCT06868264
NCT07388979
NCT05975216
NCT05071261
NCT00894257
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions